INTRODUCTION

The evolution and emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have caused concern for increased transmissibility (Davies, et al., 2021), pathogenicity (Davies et al., 2021), and altered effectiveness of diagnostics (Ascoli, 2021), therapeutics and vaccines (Altmann et al., 2021). Human-to-animal transmission of SARS-CoV-2 is well-documented

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2021 The Authors. Transboundary and Emerging Diseases published by Wiley-VCH GmbH
in pets (Hosie et al., 2021), which typically become infected after exposure to owners with COVID-19 (OIE 2021). However, the impact of infections with SARS-CoV-2 variants of concern on the clinical presentation and duration of infection in pets and the transmissibility between people and pets remains unknown. Since June 2020, we have conducted a longitudinal household transmission study of pets living with one or more persons with COVID-19 (Hamer et al., 2020) to better understand the role of virus transmission between humans and pets.

As part of this ongoing study, two pets from the same household were sampled for SARS-CoV-2 on 12 February 2021, two days after their owner—one of two residents in a home in Brazos County, Texas—received a positive test result for COVID-19 through a commercial laboratory; no viral sequence was generated from the owner. The pets—the only animals in the home—were a 15-year-old Labrador retriever mix dog and a 12-year-old domestic shorthair cat. On initial visit, the animals were asymptomatic. The owner described a high degree of contact with both pets, including sleeping in the same room (dog) and bed (cat). Following previously described methods (Hamer et al., 2020), oral, nasal and fur swabs from both pets were found to be positive for SARS-CoV-2 by real-time (RT) PCR. Rectal swabs tested negative. Sera tested negative for SARS-CoV-2 neutralizing antibodies using a 96-well virus neutralization test as previously described (Table 1; McAloose et al., 2020). Live virus isolation was attempted from all positive samples and was successful from the cat’s nasal swab. SARS-CoV-2 whole-genome sequencing was attempted and successful from the cat’s nasal swab and the dog’s oral swab. Consensus sequences from both animals were 100% identical to each other and were identified as the B.1.1.7 variant of concern by single-nucleotide polymorphism (SNP) analysis and alignment. In addition to characteristic B.1.1.7 mutations, sequences from both animals also showed 8 SNPs in ORF1ab and ORF8.

These pets were resampled on March 11, at which time the owner disclosed both had been sneezing over the past weeks. Pets were resampled again on March 15, and clinical signs had resolved. Nasal and rectal swabs from both pets were found to be positive for SARS-CoV-2 by real-time (RT) PCR. Rectal swabs tested negative. Sera tested negative for SARS-CoV-2 neutralizing antibodies using a 96-well virus neutralization test as previously described (Table 1; McAloose et al., 2020). Live virus isolation was attempted from all positive samples and was successful from the cat’s nasal swab. SARS-CoV-2 whole-genome sequencing was attempted and successful from the cat’s nasal swab and the dog’s oral swab. Consensus sequences from both animals were 100% identical to each other and were identified as the B.1.1.7 variant of concern by single-nucleotide polymorphism (SNP) analysis and alignment. In addition to characteristic B.1.1.7 mutations, sequences from both animals also showed 8 SNPs in ORF1ab and ORF8.

This study documents the first detection of B.1.1.7. in companion animals in the United States, and the first genome recovery and isolation of B.1.1.7 variant of concern globally in any animal. These findings are coincident with detection of B.1.1.7 infection in rectal swabs of three U.K. pets with myocarditis (Ferasin et al., 2021). These results support public health guidance that recommends people with COVID-19 isolate from animals (CDC, 2021) and the continued application of a One Health approach to SARS-CoV-2 investigations. Given the continued emergence (Galloway et al., 2021) and enhanced transmissibility and pathogenicity of B.1.1.7 in humans (Davies, Abbott, et al., 2021), onward transmission of this and other variants of concern from animals should remain the subject of ongoing research.

### Table 1

<table>
<thead>
<tr>
<th>Animal ID number</th>
<th>Date of sample collection</th>
<th>N1/N2 real-time (RT) PCR Ct values for swab testing</th>
<th>Viral neutralization endpoint titre</th>
<th>Viral isolation</th>
<th>Genome sequence GISAID accession</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dog TAMU-466</td>
<td>Feb 12, 2021</td>
<td>28.8/28.6</td>
<td>1:16</td>
<td>Oral, nasal, fur negative</td>
<td>hCoV-19/dog/USA/TX-TAMU-21-005988-002-466/2020</td>
</tr>
<tr>
<td></td>
<td>Mar 11, 2021</td>
<td>nd/nd</td>
<td>nd/nd</td>
<td>Oral fur negative: nasal</td>
<td>Positive</td>
</tr>
<tr>
<td></td>
<td>Mar 15, 2021</td>
<td>34.6/37.4</td>
<td>na/na</td>
<td>Oral fur negative: nasal</td>
<td>Positive</td>
</tr>
<tr>
<td>Cat TAMU-467</td>
<td>Feb 12, 2021</td>
<td>29.8/31.7</td>
<td>1:64</td>
<td>Oral, fur negative; nasal</td>
<td>Positive</td>
</tr>
<tr>
<td></td>
<td>Mar 11, 2021</td>
<td>nd/nd</td>
<td>nd/nd</td>
<td>Oral fur negative: nasal</td>
<td>Positive</td>
</tr>
<tr>
<td></td>
<td>Mar 15, 2021</td>
<td>nd/nd</td>
<td>na/na</td>
<td>Oral fur negative: nasal</td>
<td>Positive</td>
</tr>
</tbody>
</table>

Abbreviations: N1/N2, virus nucleocapsid gene target region 1 and 2; na, not attempted; nd, not detected.

*Testing was conducted at both the Wisconsin Veterinary Diagnostic Laboratory and National Veterinary Services Laboratory (NVSL). When detected in both laboratories, the Ct values were averaged by target.
ACKNOWLEDGMENTS
We appreciate the participation of the owner and their pets in this study. We thank Dr. Susan Rollo of Texas Animal Health Commission and Drs. Laura Robinson, Paul Gruenwald and David Smokno of Texas Department of State Health Services for assistance in the case investigation, and Dan Christensen from Wisconsin Veterinary Diagnostic Lab. This publication was supported by Grant No. 75D30120P09884 from the CDC-NIOSH. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the USDA.

[Correction added on 27 May 2021, after first online publication: The funding statement has been added before the last sentence of the Acknowledgments in this current version.]

CONFLICTS OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

ETHICAL APPROVAL
All samples were obtained from privately owned animals in accordance with guidelines approved by the Texas A&M University’s Institutional Animal Care and Use Committee and Clinical Research Review Committee on May 14, 2020 (2018–0460CA). Research was exempt from Institutional Review Board oversight.

DATA AVAILABILITY STATEMENT
The whole-genome sequences from this study are available at GISAID accession numbers hCoV-19/dog/USA/TX-TAMU-21–005988–002-466/2020 and hCoV-19/cat/USA/TX-TAMU-21-005988-005-467/2020.

REFERENCES

How to cite this article: Hamer SA, Ghai RR, Zecca IB, et al. SARS-CoV-2 B.1.1.7 variant of concern detected in a pet dog and cat after exposure to a person with COVID-19, USA. Transbound Emerg Dis. 2021;00:1–3. https://doi.org/10.1111/bed.14122

ORCID
Sarah A. Hamer https://orcid.org/0000-0002-4955-048X